Recent advances in managing hepatitis D
- PMID:28928961
- PMCID: PMC5580405
- DOI: 10.12688/f1000research.11796.1
Recent advances in managing hepatitis D
Abstract
Hepatitis D virus (HDV) infection leads to the most severe form of chronic viral hepatitis and requires the attention of a liver specialist. In this review, I will recapitulate recent advances in the management of HDV, present background information on HDV infection as well as current chronic hepatitis D treatment, briefly examine the HDV life cycle and discuss new management strategies.
Keywords: Hepatitis D Virus; hepatotrop; pegylated interferon.
Conflict of interest statement
Competing interests: The author has received consultancy and/or lecture fees from AbbVie, BMS, Gilead, Roche, Merck, Janssen, and Novartis, and has received grants from BMS, Roche and Eiger Biopharma over the years.No competing interests were disclosed.No competing interests were disclosed.
Similar articles
- Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.Keskin O, Wedemeyer H, Tüzün A, Zachou K, Deda X, Dalekos GN, Heidrich B, Pehlivan S, Zeuzem S, Yalçın K, Gürel S, Tabak F, Idilman R, Bozkaya H, Manns M, Yurdaydin C.Keskin O, et al.Clin Gastroenterol Hepatol. 2015 Dec;13(13):2342-49.e1-2. doi: 10.1016/j.cgh.2015.05.029. Epub 2015 Jun 1.Clin Gastroenterol Hepatol. 2015.PMID:26044319Clinical Trial.
- Hepatitis D virus: an update.Pascarella S, Negro F.Pascarella S, et al.Liver Int. 2011 Jan;31(1):7-21. doi: 10.1111/j.1478-3231.2010.02320.x. Epub 2010 Sep 29.Liver Int. 2011.PMID:20880077Review.
- Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.Grabowski J, Yurdaydìn C, Zachou K, Buggisch P, Hofmann WP, Jaroszewicz J, Schlaphoff V, Manns MP, Cornberg M, Wedemeyer H; HIDIT-1 study group.Grabowski J, et al.Liver Int. 2011 Oct;31(9):1395-405. doi: 10.1111/j.1478-3231.2011.02593.x. Epub 2011 Jul 15.Liver Int. 2011.PMID:21762356Clinical Trial.
- Mouse models of hepatitis B and delta virus infection.Dandri M, Lütgehetmann M.Dandri M, et al.J Immunol Methods. 2014 Aug;410:39-49. doi: 10.1016/j.jim.2014.03.002. Epub 2014 Mar 12.J Immunol Methods. 2014.PMID:24631647
- An update on HDV: virology, pathogenesis and treatment.Alvarado-Mora MV, Locarnini S, Rizzetto M, Pinho JR.Alvarado-Mora MV, et al.Antivir Ther. 2013;18(3 Pt B):541-8. doi: 10.3851/IMP2598. Epub 2013 Jun 21.Antivir Ther. 2013.PMID:23792471Review.
Cited by
- The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?Hayashi T, Takeshita Y, Hutin YJ, Harmanci H, Easterbrook P, Hess S, van Holten J, Oru EO, Kaneko S, Yurdaydin C, Bulterys M.Hayashi T, et al.Arch Public Health. 2021 Oct 19;79(1):180. doi: 10.1186/s13690-021-00693-2.Arch Public Health. 2021.PMID:34663473Free PMC article.
- Hepatitis D infection: from initial discovery to current investigational therapies.Da BL, Heller T, Koh C.Da BL, et al.Gastroenterol Rep (Oxf). 2019 Jun 23;7(4):231-245. doi: 10.1093/gastro/goz023. eCollection 2019 Aug.Gastroenterol Rep (Oxf). 2019.PMID:32477569Free PMC article.
References
Publication types
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources